The stock of Aequus Pharmaceuticals Inc (CVE:AQS) is a huge mover today! About 121,666 shares traded hands. Aequus Pharmaceuticals Inc (CVE:AQS) has risen 6.00% since September 19, 2016 and is uptrending. It has outperformed by 0.46% the S&P500.
The move comes after 9 months positive chart setup for the $16.08 million company. It was reported on Oct, 19 by Barchart.com. We have $0.76 PT which if reached, will make CVE:AQS worth $20.26M more.
More notable recent Aequus Pharmaceuticals Inc (CVE:AQS) news were published by: Investingnews.com which released: “Aequus Pharmaceuticals Inc. Announces $2.0 to $4.0 Million Best Efforts Financing” on September 06, 2016, also Reuters.com with their article: “BRIEF-Aequus Pharmaceuticals says advancement of clobazam transdermal pate…” published on July 29, 2016, Marketwired.com published: “Aequus Pharmaceuticals Lists on the TSX Venture Exchange and Appoints New Director” on March 17, 2015. More interesting news about Aequus Pharmaceuticals Inc (CVE:AQS) were released by: Marketwired.com and their article: “Aequus Pharmaceuticals Initiates Promotional Efforts for VISTITAN(TM) in Canada” published on April 28, 2016 as well as Business.Financialpost.com‘s news article titled: “Podcast: Aequus Pharmaceuticals CEO Doug Janzen on the low cost of drug …” with publication date: May 03, 2016.
Aequus Pharmaceuticals Inc. is a specialty pharmaceutical firm focused on developing and commercializing products. The company has a market cap of $16.08 million. The Firm operates through the segment of sales and marketing of pharmaceutical drugs developed by the Company or by its collaborative partners. It currently has negative earnings. The Company’s products include tacrolimus immediate releaser, which is an immunosuppressive therapy used for the treatment and prevention of acute rejection following organ transplantation; Vistitan, which is a ophthalmology product; Topiramate extended-release , which is a once-daily topiramate product designed for patient compliance, and Oxcarbazepine XR, which is a once-daily oxcarbazepine product.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.